Changchun BCHT Biotechnology Co., Ltd. (BKSW) – Recent Developments

Regulatory Approval for a Novel Vaccine

On 13 November 2025, the Shanghai Stock Exchange-listed Changchun BCHT Biotechnology Co., Ltd. (ticker SH688276) announced that its “Absorption‑Free Whole‑Cell Bacillus‑Candidatus Vaccine (Adult & Adolescent)” has received approval for its clinical trial application. The approval, documented in a formal disclosure, authorises the company to proceed with Phase‑III testing of this two‑component vaccine, which targets a broad spectrum of respiratory pathogens. The decision marks a critical regulatory milestone that could accelerate the product’s entry into the market, particularly as influenza activity rises across China.

Progress on Rabies Vaccine – Phase‑III Trial Commences

In a separate disclosure dated 11 November 2025, BKSW confirmed the initiation of a Phase‑III clinical trial for its freeze‑dry, human‑cell‑derived rabies vaccine (clinical trial registration number CTR20254433). The study, described as randomised, double‑blind and positive‑controlled, will evaluate the immunogenicity and safety of three different immunisation schedules (five‑dose, 2‑1‑1 and simplified four‑dose regimens). The trial is a significant step toward establishing the vaccine’s efficacy and could provide a new preventive option for a disease with a near‑100 % fatality rate if untreated.

Market Context – Vaccine‑Sector Rally

The week of 10–13 November witnessed a pronounced rally in the vaccine segment. On 11 November, stocks such as Golddech, Watson Biologics, Zhifei Biologics, Kangtaibio, and BKSW surged in tandem with the sector’s upward momentum, as reported by several market‑watch outlets. The rally was fueled by heightened influenza activity, with the National Center for Disease Control announcing a spike in influenza‑like illness across most provinces. Consequently, investor sentiment has turned favourable toward companies positioned to supply vaccines and related biologics.

Liquidity and Investor Activity

On 10 November, BKSW attracted a notable amount of financing, recording a funding inflow of 28.39 million CNY. The financing balance stood at 236.25 million CNY, representing 2.49 % of the free‑float market value—an increase above the 70th percentile of historical levels. This liquidity injection suggests confidence from institutional investors and may provide capital for ongoing R&D and commercial activities.

Stock Performance and Technical Indicators

  • Close price (10 Nov 2025): 23.20 CNY
  • 52‑week high (13 Nov 2024): 28.71 CNY
  • 52‑week low (20 Apr 2025): 20.19 CNY

The share price has been operating near the 52‑week high, reflecting a bullish technical stance. Within the broader Shanghai Composite Index context, 39 stocks have crossed the annual line during the period, indicating a broad‑based upside. BKSW’s inclusion among these performers underscores its alignment with sectoral and macro‑economic trends.

Financial Snapshot

  • Market Capitalisation: 9,480,000,000 CNY
  • Price‑Earnings Ratio: –52.93 (negative, indicative of current losses but common in high‑growth biotech firms)

Outlook

BKSW’s regulatory approvals and clinical milestones, coupled with the vaccine‑sector’s market rally and fresh capital inflow, position the company favorably for the upcoming influenza season and beyond. Continued progress in the rabies vaccine trial and potential commercialization of the new whole‑cell vaccine could enhance revenue streams and improve profitability in the medium term. Investors should monitor the company’s clinical timelines, regulatory updates, and market responses to the evolving influenza landscape.